Skip to main content

Advertisement

SpringerLink
Log in

Cannabis and Mood Disorders

  • Dual Diagnosis (T George and A Hassan, Section Editors)
  • Published:
Current Addiction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The present review will provide an overview of the neurobiology, epidemiology, clinical impact, and treatment of cannabis use disorder (CUD) in mood disorders.

Recent Findings

Patients with mood disorders including major depressive disorder (MDD) and bipolar disorder (BD) have higher rates of cannabis use, and CUD compared to the general population. Reasons for this association are not clear, nor are the putative therapeutic effects of cannabis use, or its components delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in these illnesses. The evidence surrounding treatments for patients with this comorbidity is lacking, with more support for psychotherapeutic treatments compared with pharmacological treatments.

Summary

Cannabis use may be associated with mood disorders, but more research is needed to increase our understanding of the mechanisms for this association, and to develop more effective treatments for this comorbidity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Hasin D, Saha T, Kerridge B, Goldstein R, Chou S, Zhang H. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiat. 2015;72:p. 1235–42. This is a population-based longitudinal study that provides evidence of increasing prevalence of cannabis use disorder following the legalization of recreational cannabis in US states, highlighting the importance of understanding the consequences of legalization.

  2. Mason WA, Fleming CB, Ringle JL, Hanson K, Gross TJ, Haggerty KP. Prevalence of marijuana and other substance use before and after Washington State’s change from legal medical marijuana to legal medical and non-medical marijuana: cohort comparisons in a sample of adolescents. Subst Abus. 2016;37:330–5. https://doi.org/10.1080/08897077.2015.1071723.

    Article  PubMed  Google Scholar 

  3. Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P et al. Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. 2016.

  4. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last two decades (1995–2014)—analysis of current data in the United States. Biol Psychiatry. 2016;79:613–9. https://doi.org/10.1016/j.biopsych.2016.01.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science (New York, NY). 2002;296:678–82. https://doi.org/10.1126/science.1063545.

    Article  CAS  Google Scholar 

  6. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530–4. https://doi.org/10.1038/nature00839.

    Article  CAS  PubMed  Google Scholar 

  7. Solinas M, Yasar S, Goldberg SR. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res. 2007;56:393–405. https://doi.org/10.1016/j.phrs.2007.09.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Miller LL, Branconnier RJ. Cannabis: effects on memory and the cholinergic limbic system. Psychol Bull. 1983;93:441–56.

    Article  CAS  PubMed  Google Scholar 

  9. Block RI, Ghoneim MM. Effects of chronic marijuana use on human cognition. Psychopharmacology. 1993;110:219–28.

    Article  CAS  PubMed  Google Scholar 

  10. Darley CF, Tinklenberg JR, Roth WT, Atkinson RC. The nature of storage deficits and state-dependent retrieval under marihuana. Psychopharmacologia. 1974;37:139–49.

    Article  CAS  PubMed  Google Scholar 

  11. Moreira FA, Crippa JAS. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr. 2009;31:145–53.

    Article  PubMed  Google Scholar 

  12. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Cannabis use and cannabis use disorders among individuals with mental illness. Compr Psychiatry. 2013;54:589–98. https://doi.org/10.1016/j.comppsych.2012.12.021.

    Article  PubMed  Google Scholar 

  13. World Health Organization. Depression fact sheet 2017.

  14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders :DSM-5. Fifth edit ed. Arlington, VA: American Psychiatric Publishing; 2013.

    Book  Google Scholar 

  15. Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry. 2001;158:2033–7. https://doi.org/10.1176/appi.ajp.158.12.2033.

    Article  CAS  PubMed  Google Scholar 

  16. Wittchen HU, Fröhlich C, Behrendt S, Günther A, Rehm J, Zimmermann P, et al. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend. 2007;88:60–70. https://doi.org/10.1016/j.drugalcdep.2006.12.013.

    Article  Google Scholar 

  17. Cornelius JR, Chung T, Martin C, Wood DS, Clark DB. Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict Behav. 2008;33:1500–5. https://doi.org/10.1016/j.addbeh.2008.02.001.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Dorard G, Berthoz S, Phan O, Corcos M, Bungener C. Affect dysregulation in cannabis abusers: a study in adolescents and young adults. Eur Child Adolesc Psychiatry. 2008;17:274–82. https://doi.org/10.1007/s00787-007-0663-7.

    Article  PubMed  Google Scholar 

  19. Lee KSK, Clough AR, Jaragba MJ, Conigrave KM, Patton GC. Heavy cannabis use and depressive symptoms in three aboriginal communities in Arnhem Land, Northern Territory. Med J Aust. 2008;188:605–8.

    Article  PubMed  Google Scholar 

  20. Ehlers CL, Gizer IR, Vieten C, Gilder DA, Stouffer GM, Lau P, et al. Cannabis dependence in the San Francisco family study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability. Addict Behav. 2010;35:102–10. https://doi.org/10.1016/j.addbeh.2009.09.009.

    Article  PubMed  Google Scholar 

  21. Horwood LJ, Fergusson DM, Coffey C, Patton GC, Tait R, Smart D, et al. Cannabis and depression: an integrative data analysis of four Australasian cohorts. Drug Alcohol Depend. 2012;126:369–78. https://doi.org/10.1016/j.drugalcdep.2012.06.002.

    Article  PubMed  Google Scholar 

  22. Osuch E, Vingilis E, Ross E, Forster C, Summerhurst C. Cannabis use, addiction risk and functional impairment in youth seeking treatment for primary mood or anxiety concerns. Int J Adolesc Med Health. 2013;25:309–14. https://doi.org/10.1515/ijamh-2013-0067.

    Article  PubMed  Google Scholar 

  23. •• Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychological Med. 2014;44:797–810. https://doi.org/10.1017/S0033291713001438. This is an important meta-analysis of longitudinal studies that ultimately determined that there is a moderate effect for the risk of cannabis users to develop depression.

    Article  CAS  Google Scholar 

  24. Danielsson A-K, Lundin A, Agardh E, Allebeck P, Forsell Y. Cannabis use, depression and anxiety: a 3-year prospective population-based study. J Affect Disord. 2016;193:103–8. https://doi.org/10.1016/j.jad.2015.12.045.

    Article  CAS  PubMed  Google Scholar 

  25. • Moitra E, Anderson BJ, Stein MD. Reduction in cannabis use are associated with mood improvement in female emerging adults. Depress Anxiety. 2016;33:332–8. https://doi.org/10.1002/da.22460. Secondary analysis of a RCT for motivational interviewing in cannabis dependent youth, and found that decreasing cannabis use improved depressive symptoms.

  26. Stapinski LA, Montgomery AA, Araya R. Anxiety, depression and risk of cannabis use: examining the internalising pathway to use among Chilean adolescents. Drug Alcohol Depend. 2016;166:109–15. https://doi.org/10.1016/j.drugalcdep.2016.06.032.

    Article  PubMed  Google Scholar 

  27. Womack SR, Shaw DS, Weaver CM, Forbes EE. Bidirectional associations between cannabis use and depressive symptoms from adolescence through early adulthood among at-risk young men. Alcohol Drugs. 2016;77:287297. https://doi.org/10.15288/jsad.2016.77.287.

  28. Hill KP. Cannabis use and risk for substance use disorders and mood or anxiety disorders. JAMA. 2017;317:1070–1. https://doi.org/10.1001/jama.2016.19706.

    Article  PubMed  Google Scholar 

  29. •• Feingold D, Rehm J, Lev-Ran S. Cannabis use and the course and outcome of major depressive disorder: a population based longitudinal study. Psychiatry Res. 2017;251:225–34. https://doi.org/10.1016/j.psychres.2017.02.027. This study examined the specific effects of cannabis use on MDD in a population-based sample, and found an increase in a broad range of MDD-related outcomes.

    Article  PubMed  Google Scholar 

  30. • Rabin RA, Kozak K, Zakzanis KK, Remington G, George TP. Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophr Res. 2017; https://doi.org/10.1016/j.schres.2017.03.010. The first study of its kind to examine the prospective effects of cannabis abstinence on a psychiatric population. They found a decrease in depressive symptoms after a 28-day abstinence period in patients with schizophrenia.

  31. Smolkina M, Morley KI, Rijsdijk F, Agrawal A, Bergin JE, Nelson EC, et al. Cannabis and depression: a twin model approach to co-morbidity. Behav Genet. 2017;47:394–404. https://doi.org/10.1007/s10519-017-9848-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kessler R, Chiu W, Demler O, Walters E. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry. 2005;62:617–27.

    Article  PubMed  PubMed Central  Google Scholar 

  33. •• Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Research. 2013;209:459–65. https://doi.org/10.1016/j.psychres.2012.12.014. An important population-based longitudinal study that provides evidence for lower age of onset of bipolar disorder symptoms in cannabis users. They also found an association between CUD and increased bipolar-related symptoms.

    Article  PubMed  Google Scholar 

  34. Feingold D, Weiser M, Jr R, Lev-Ran S. The association between cannabis use and mood disorders: a longitudinal study. J Affect Disord. 2015;172:211–8. https://doi.org/10.1016/j.jad.2014.10.006.

    Article  PubMed  Google Scholar 

  35. van Rossum I, Boomsma M, Tenback D, Reed C, van Os J. Does cannabis use affect treatment outcome in bipolar disorder? J Nerv Ment Dis. 2009;197:35–40. https://doi.org/10.1097/NMD.0b013e31819292a6.

    Article  PubMed  Google Scholar 

  36. Braga RJ, Burdick KE, DeRosse P, Malhotra AK. Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Res. 2012;200:242–5. https://doi.org/10.1016/j.psychres.2012.05.025.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Heffner JL, Anthenelli RM, Adler CM, Strakowski SM, Beavers J, DelBello MP. Prevalence and correlates of heavy smoking and nicotine dependence in adolescents with bipolar and cannabis use disorders. Psychiatry Res. 2013;210:857–62. https://doi.org/10.1016/j.psychres.2013.04.010.

    Article  PubMed  PubMed Central  Google Scholar 

  38. • Lagerberg TV, Kvitland LR, Aminoff SR, Aas M, Ringen PA, Andreassen OA, et al. Indications of a dose–response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Res. 2014;215:101–4. https://doi.org/10.1016/j.psychres.2013.10.029. This cross-sectional study found earlier age of onset for a range of bipolar-related symptoms in cannabis users, providing evidence that cannabis use can impact the outcomes for patients with bipolar disorder.

    Article  CAS  PubMed  Google Scholar 

  39. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39–47. https://doi.org/10.1016/j.jad.2014.09.016.

    Article  PubMed  Google Scholar 

  40. •• Zorrilla I, Aguado J, Haro JM, Barbeito S, López Zurbano S, Ortiz A, et al. Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? Acta Psychiatr Scand. 2015;131:100–10. https://doi.org/10.1111/acps.12366. This important longitudinal study found a reversal in bipolar-symptom exacerbation related to cannabis use after a period of cannabis abstinence. This demonstrates that reducing or ceasing cannabis use can improve outcomes in this population.

    Article  CAS  PubMed  Google Scholar 

  41. • Kvitland LR, Melle I, Aminoff SR, Lagerberg TV, Andreassen OA, Ringen PA. Cannabis use in first-treatment bipolar I disorder: relations to clinical characteristics. Early Interv Psychiatry. 2016;10:36–44. https://doi.org/10.1111/eip.12138. This cross-sectional study found earlier age of onset for manic symptoms in cannabis users, providing evidence that cannabis use can impact the outcomes for patients with bipolar disorder.

    Article  PubMed  Google Scholar 

  42. American Psychological Association. Practice guideline for the treatment of patients with major depressive disorder, Third Edition 2010.

  43. Jann MW. Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. Am Health Drug Benefits. 2014;7(9):489–99.

    PubMed  PubMed Central  Google Scholar 

  44. Shah N, Grover S, Rao GP. Clinical practice guidelines for management of bipolar disorder. Indian J Psychiatry. 2017;59:S51–66. https://doi.org/10.4103/0019-5545.196974.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes E. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116:142–50. https://doi.org/10.1016/j.drugalcdep.2010.12.010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Hill KP, Palastro MD, Gruber SA, Fitzmaurice GM, Greenfield SF, Lukas SE, et al. Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study. Am J Addict. 2017;26:795–801. https://doi.org/10.1111/ajad.12622.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, et al. Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2016;159:53–60. https://doi.org/10.1016/j.drugalcdep.2015.11.025.

    Article  CAS  PubMed  Google Scholar 

  48. Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend. 2013;128:64–70. https://doi.org/10.1016/j.drugalcdep.2012.08.001.

    Article  CAS  PubMed  Google Scholar 

  49. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology. 2013;38:1557–65. https://doi.org/10.1038/npp.2013.54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Gray KM, Watson NL, Carpenter MJ, LaRowe SD. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J addict / Am Acad Psychiatrists Alcohol Addict. 2010;19:187–9. https://doi.org/10.1111/j.1521-0391.2009.00027.x.

    Article  Google Scholar 

  51. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169:805–12. https://doi.org/10.1176/appi.ajp.2012.12010055.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017;177:249–57. https://doi.org/10.1016/j.drugalcdep.2017.04.020.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37:1689–98. https://doi.org/10.1038/npp.2012.14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, et al. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology. 2010;211:233–44. https://doi.org/10.1007/s00213-010-1888-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Allsop D, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71:281–91.

    Article  CAS  PubMed  Google Scholar 

  56. Miranda R, Treloar H, Blanchard A, Justus A, Monti PM, Chun T, et al. Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study. Addict Biol. 2017;22(3):779–90. https://doi.org/10.1111/adb.12350.

    Article  CAS  PubMed  Google Scholar 

  57. • Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol depend. 2010;112:39–45. https://doi.org/10.1016/j.drugalcdep.2010.05.010. This study examined the potential of fluoxetine for reducing symptoms of comorbid MDD and CUD, but held negative results. A pioneer studies that use pharmacological treatments in a comorbid MDD population with CUD.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. • Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, et al. A randomized double-blind, placebo controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addict (Abingdon, England). 2013;108:1084–94. https://doi.org/10.1111/add.12108. This study examined the potential of venlafaxine for reducing symptoms of comorbid MDD and CUD, but held negative results. This was one of the first studies to evaluate pharmacological treatments in a comorbid MDD population with CUD.

    Article  Google Scholar 

  59. Winstock AR, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol (Oxford, England). 2009;23:84–93. https://doi.org/10.1177/0269881108089584.

    Article  CAS  Google Scholar 

  60. Mariani JJ, Pavlicova M, Mamczur AK, Bisaga A, Nunes EV, Levin FR. Open-label pilot study of quetiapine treatment for cannabis dependence. Am J Drug Alcohol Abuse. 2014;40:280–4. https://doi.org/10.3109/00952990.2014.884102.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Hoch E, Bühringer G, Pixa A, Dittmer K, Henker J, Seifert A, et al. CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial. Drug Alcohol Depend. 2014;134:185–93. https://doi.org/10.1016/j.drugalcdep.2013.09.028.

    Article  CAS  PubMed  Google Scholar 

  62. Weiss RD, Griffin ML, Greenfield SF, Najavits LM, Wyner D, Soto JA, et al. Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. J Clin Psychiatry. 2000;61:361–7.

    Article  CAS  PubMed  Google Scholar 

  63. Hendriks V, van der Schee E, Blanken P. Matching adolescents with a cannabis use disorder to multidimensional family therapy or cognitive behavioral therapy: treatment effect moderators in a randomized controlled trial. Drug Alcohol Depend. 2012;125:119–26. https://doi.org/10.1016/j.drugalcdep.2012.03.023.

    Article  PubMed  Google Scholar 

  64. Hoch E, Noack R, Henker J, Pixa A, Höfler M, Behrendt S, et al. Efficacy of a targeted cognitive–behavioral treatment program for cannabis use disorders (CANDIS*). Eur Neuropsychopharmacol. 2012;22:267–80. https://doi.org/10.1016/j.euroneuro.2011.07.014.

    Article  CAS  PubMed  Google Scholar 

  65. Martin G, Copeland J. The adolescent cannabis check-up: randomized trial of a brief intervention for young cannabis users. J Subst Abus Treat. 2008;34:407–14. https://doi.org/10.1016/j.jsat.2007.07.004.

    Article  Google Scholar 

  66. Carroll, K. M., Onken, L. S. (2005). Behavioral Therapies for Drug Abuse. Am. J. Psychiatry. 162:1452-1460.

  67. Bobb AJ, Hill KP. Behavioral interventions and pharmacotherapies for cannabis use disorder. Curr Treat Options in Psychiatry. 2014;1(2):163–74. https://doi.org/10.1007/s40501-014-0013-6.

    Article  Google Scholar 

  68. George, T. P., Hill, K.P., Vaccarino, F.J. (in press) Cannabis legalization and psychiatric disorders: caveat “H-Emptor”. The Canadian Journal of Psychiatry, 2018.

Download references

Funding

This manuscript was supported by an Institute of Medical Sciences Graduate Fellowship from the University of Toronto (to Ms. Lucatch), by NIDA grant R21-DA-043949, CIHR grant MOP#115145, and funds from the Astrid H. Flaska Foundation (to Dr. George).

Author information

Authors and Affiliations

  1. Addictions Division, Centre for Addictions and Mental Health (CAMH), 100 Stokes Street, BGB 3288, Toronto, ON, MJ6 1H4, Canada

    Aliya M. Lucatch, Alexandria S. Coles & Tony P. George

  2. Division of Addiction Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

    Kevin P. Hill

  3. Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Toronto, ON, Canada

    Tony P. George

Authors
  1. Aliya M. Lucatch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandria S. Coles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kevin P. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tony P. George
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tony P. George.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

This article is part of the Topical Collection on Dual Diagnosis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lucatch, A.M., Coles, A.S., Hill, K.P. et al. Cannabis and Mood Disorders. Curr Addict Rep 5, 336–345 (2018). https://doi.org/10.1007/s40429-018-0214-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40429-018-0214-y

Keywords

Search

Navigation